| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PD.4611 |
| P698 | PubMed publication ID | 25962526 |
| P50 | author | Cecilia Götherström | Q47159961 |
| P2093 | author name string | Magnus Westgren | |
| P2860 | cites work | Bisphosphonate therapy for osteogenesis imperfecta | Q24194821 |
| Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding | Q24296711 | ||
| Defining the risks of mesenchymal stromal cell therapy | Q47584701 | ||
| Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. | Q48712762 | ||
| Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. | Q51210701 | ||
| Immunologic properties of human fetal mesenchymal stem cells. | Q51718048 | ||
| Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. | Q51998594 | ||
| Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. | Q52001009 | ||
| Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. | Q53101655 | ||
| Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. | Q53171235 | ||
| Angulated femurs and the skeletal dysplasias: experience of the International Skeletal Dysplasia Registry (1988-2006). | Q53236734 | ||
| Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. | Q53328521 | ||
| First-trimester diagnosis of osteogenesis imperfecta associated with encephalocele by conventional and three-dimensional ultrasound. | Q54591302 | ||
| Fetal therapy: 2020 and beyond | Q58009820 | ||
| Prenatal diagnosis of osteogenesis imperfecta | Q58496091 | ||
| Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta | Q58789209 | ||
| Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta | Q24632692 | ||
| Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation | Q26824200 | ||
| New genes in bone development: what's new in osteogenesis imperfecta | Q26864752 | ||
| Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment | Q27025005 | ||
| Multilineage potential of adult human mesenchymal stem cells | Q27860737 | ||
| Osteogenesis imperfecta: prospects for molecular therapeutics | Q28139390 | ||
| Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 | ||
| Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta | Q33772970 | ||
| Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta | Q33855709 | ||
| Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone | Q34066339 | ||
| Cyclic administration of pamidronate in children with severe osteogenesis imperfecta | Q34067536 | ||
| Immunomodulatory effects of fetal and adult mesenchymal stem cells | Q35601901 | ||
| Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta | Q35796570 | ||
| Procollagen trafficking, processing and fibrillogenesis. | Q36078993 | ||
| Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. | Q36206449 | ||
| Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). | Q36372136 | ||
| Fetal stem-cell transplantation | Q37012798 | ||
| In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta | Q37271063 | ||
| Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta | Q37523900 | ||
| Prenatal sonographic diagnosis of skeletal dysplasias | Q37528232 | ||
| Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience | Q37585445 | ||
| Classification of Osteogenesis Imperfecta revisited | Q37624972 | ||
| Early prenatal diagnosis of skeletal anomalies | Q37826401 | ||
| New perspectives on osteogenesis imperfecta | Q37889113 | ||
| Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. | Q37949199 | ||
| The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application | Q37973181 | ||
| Recessive osteogenesis imperfecta: clinical, radiological, and molecular findings | Q38025998 | ||
| Prenatal diagnosis of osteogenesis imperfecta type II by three-dimensional computed tomography: the current state of fetal computed tomography | Q38062559 | ||
| Intrauterine blood transfusion: current indications and associated risks | Q38218054 | ||
| What is new in genetics and osteogenesis imperfecta classification? | Q38232156 | ||
| Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells | Q38512406 | ||
| EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. | Q39701074 | ||
| Non-invasive prenatal diagnosis of osteogenesis imperfecta | Q40888768 | ||
| Mutation Analysis of COL1A1 and COL1A2 in Fetuses with Osteogenesis Imperfecta Type II/III. | Q41509333 | ||
| Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources | Q42437471 | ||
| Characterising and treating osteogenesis imperfecta | Q42905532 | ||
| Biochemical screening of type I collagen in osteogenesis imperfecta: detection of glycine substitutions in the amino end of the alpha chains requires supplementation by molecular analysis | Q43169907 | ||
| Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta | Q45875073 | ||
| Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice | Q46925534 | ||
| P433 | issue | 9 | |
| P921 | main subject | osteogenesis imperfecta | Q749409 |
| P304 | page(s) | 827-832 | |
| P577 | publication date | 2015-05-11 | |
| P1433 | published in | Prenatal Diagnosis | Q15760059 |
| P1476 | title | Stem cell transplantation before birth - a realistic option for treatment of osteogenesis imperfecta? | |
| P478 | volume | 35 |
| Q64039618 | Current and Emerging Therapeutic Options for the Management of Rare Skeletal Diseases |
| Q57839567 | Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities |
| Q38998578 | Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. |
| Q34558273 | Promises, pitfalls and practicalities of prenatal whole exome sequencing |
| Q88212766 | Rapid prenatal diagnosis using targeted exome sequencing: a cohort study to assess feasibility and potential impact on prenatal counseling and pregnancy management |
| Q91688583 | Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches |
| Q36183143 | Transcription factor ZNF25 is associated with osteoblast differentiation of human skeletal stem cells |
Search more.